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Cervical Cancer is the third most common cancer
worldwide and is almost always caused by human papil-
loma virus (HPV) infection. The HPV genes E6 and E7
are known to be oncogenes that promote cellular
changes in infected cells leading to malignant transfor-
mation. We have previously reported that ADXS11-001
immunotherapy, a live attenuated Listeria monocyto-
genes (Lm), bioengineered to secrete a LLO-E7 fusion
protein, can be safely administered to patients with late
stage cervical cancer. In a Phase 2 study being con-
ducted in India, 110 patients with recurrent cervical
cancer received 264 doses of ADXS11-001. In this study,
serum samples were collected from each patient at three
different time points: pre-dose; 2h and 4h post-dose of
ADXS11-001 immunotherapy. The initial analysis of 18
serum samples using 45-biomarker multi-analyte human
inflammation MAPv1.0 (Myriad RBM) showed differen-
tial increases in cytokine and chemokine levels in each
sample at 2 and 4 hours post-dosing with ADXS11-001.
More than a 15-fold increase was observed in the level
of cytokines (IL-6, IL-8, IL-10 and TNF-a) and chemo-
kines (MIP-1a, MIP-1b and MCP-1), indicating strong
stimulation of innate immunity. We will report our eva-
luation of RNA from serum samples collected from
patients at pre- and post-dosing of ADXS11-001 using a
genomics-based approach and evaluate correlation with
changes in cytokine and chemokine levels. We will
further report the association of changes in the expres-
sion of cytokines or other serum factors with the sever-
ity of adverse events as well as clinical responses. In
conclusion, RNA or protein expression profiles from
patient serum may help in identifying biomarkers which
may be employed as a screening tool in future studies
to predict efficacy, monitor side effects, and suggest
more precise toxicity management for patients treated
with of ADXS11-001 immunotherapy.
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